Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512883 · ClinicalTrials.gov registry record · Phase 3
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
A Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
- 13
- Study locations
NCT06512883 is a Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 14 participants. The trial reports 13 study locations across 4 states.
The verdict
NCT06512883, a Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
- 13
- Study locations
Study Summary
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
Conditions Studied
Interventions
- DRUG Benralizumab
Study Locations (13)
Other
- Research Site - São Paulo
- Research Site - Lille
- Research Site - Montpellier
- Research Site - Ahmedabad
- Research Site - Guadalajara
- Research Site - Rotterdam
- Research Site - Kielce
- Research Site - Altındağ
- Research Site - Istanbul
Ohio
- Research Site - Cincinnati
- Research Site - Highland Hills
Colorado
- Research Site - Aurora
Ontario
- Research Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2028-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06512883
The ClinicalTrials.gov registry entry for NCT06512883 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Eosinophilic Granulomatosis With Polyangiitis (EGPA) appearing as the primary indexed condition, and to 1 intervention - of which Benralizumab is the first listed.
NCT06512883 reports 13 study locations spanning 4 distinct geographic areas - top geographies include Other, Ohio, Colorado.
Frequently Asked Questions
What is clinical trial NCT06512883 about?
NCT06512883 is a clinical study titled "A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases". The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
What is the current status of trial NCT06512883?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2025-04-17. Estimated completion is 2028-04-03.
What conditions does trial NCT06512883 study?
This clinical trial studies the following conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES).
What interventions are being tested in trial NCT06512883?
The interventions under investigation include: Benralizumab (DRUG).
Who is sponsoring clinical trial NCT06512883?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512883 being conducted?
This trial has 13 study locations across Colorado, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
All registered trials for this condition
Hypereosinophilia Syndrome (HES)
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.